100125-96-0 Usage
General Description
Ethyl 3-bromo-4-methoxyphenylacetate is a chemical compound with the molecular formula C11H13BrO3. It is a synthetic organic molecule that belongs to the class of phenylacetates, which are commonly used in the production of pharmaceuticals and agrochemicals. Ethyl 3-broMo-4-Methoxyphenylacetate is a derivative of phenylacetic acid and contains a bromine atom and a methoxy group on the aromatic ring. It is commonly used as an intermediate in the synthesis of various pharmaceuticals and is also utilized as a research chemical in the study of organic reactions and drug development. However, as with all chemical compounds, it should be handled and used with proper safety precautions and under the guidance of trained professionals.
Check Digit Verification of cas no
The CAS Registry Mumber 100125-96-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,1,2 and 5 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 100125-96:
(8*1)+(7*0)+(6*0)+(5*1)+(4*2)+(3*5)+(2*9)+(1*6)=60
60 % 10 = 0
So 100125-96-0 is a valid CAS Registry Number.
100125-96-0Relevant articles and documents
DP2 Antagonist and Uses Thereof
-
Page/Page column 32, (2011/02/26)
Described herein is the DP2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a
HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
-
Page/Page column 91, (2010/04/28)
Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and
ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS
-
Page/Page column 17, (2010/06/22)
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
